merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Safety and FDA approval, positioning vials as a more regulated and controlled alternative to compounded drugs</answer>

<question_number>2</question_number>
<answer>By offering a direct-to-consumer platform (LillyDirect) with lower-priced, FDA-approved vials that compete with compounded medication offerings</answer>

<question_number>3</question_number>
<answer>Lack of FDA oversight and potential safety risks associated with compounded medications</answer>

<question_number>4</question_number>
<answer>Proactively undercutting compounding pharmacies and potentially attracting out-of-pocket patients while maintaining market control</answer>

<question_number>5</question_number>
<answer>The FDA shortage list allows compounding pharmacies to legally produce alternative versions of medications, which Lilly aims to eliminate by resolving the shortage status</answer>

<question_number>6</question_number>
<answer>Transparent pricing by removing third-party supply chain entities and selling directly to consumers</answer>

<question_number>7</question_number>
<answer>Potential increased risk for older patients, particularly muscle mass loss for those over 65, despite Medicare not covering weight-loss medications</answer>

<question_number>8</question_number>
<answer>By emphasizing safety, quality, and effectiveness of FDA-approved medications compared to unregulated compounded alternatives</answer>

<question_number>9</question_number>
<answer>FDA shortage list status</answer>

<question_number>10</question_number>
<answer>Offering lower-priced, FDA-approved vials to signal market competition and challenge compounding pharmacies</answer>